TRV250

About Trevena

Trevena's mission is to develop safer and more effective CNS therapies by exploiting biased ligand signaling at G protein-coupled receptors (GPCRs). Its primary achievement is the 2020 FDA approval of OLINVYK, a biased mu-opioid receptor agonist for acute pain, though commercial uptake has been limited. The company's current strategy is to advance its early-stage pipeline, including TRV045 for neuropathic pain and epilepsy, while navigating severe financial constraints and seeking strategic alternatives to sustain operations.

Therapeutic Areas

Other Acute Migraine Drugs